Company Details
novo-nordisk
64,615
2,243,164
3254
novonordisk.com
0
NOV_1789310
In-progress

Novo Nordisk Company CyberSecurity Posture
novonordisk.comNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
Company Details
novo-nordisk
64,615
2,243,164
3254
novonordisk.com
0
NOV_1789310
In-progress
Between 800 and 849

Novo Nordisk Global Score (TPRM)XXXX



No incidents recorded for Novo Nordisk in 2025.
No incidents recorded for Novo Nordisk in 2025.
No incidents recorded for Novo Nordisk in 2025.
Novo Nordisk cyber incidents detection timeline including parent company and subsidiaries

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html


We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trad

Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitm

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrol

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching t
At Teva, we're proud to be a different kind of global pharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, our commitment to bettering health has never wavered. Every day, we challenge ourselves to p

At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving ac

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic
CVS Pharmacy is America’s leading retail pharmacy with more than 9,600 locations nationwide. For more than 50 years, CVS Pharmacy has offered customers the products and services they need to stay on their path to better health. In addition to our pharmacies, our stores feature on-trend beauty depart
.png)
Fisch Solutions releases a comprehensive cybersecurity protection guide for Tri-State businesses, featuring 24/7 SOC monitoring and advanced...
This press release was orginally distributed by ReleaseWire. Ft. Lauderdale, FL -- (ReleaseWire) -- 11/02/2025 -- CPT of South Florida is a...
On October 15, 2025, Novo Nordisk and Omeros Corporation announced that they have entered into a definitive asset purchase and license...
Companies and governments are spending an escalating fortune on IT security but cybercrime is only growing worse.
In a week marked by a surge of positive corporate news, three industry giants—Intel, Palo Alto Networks, and Novo Nordisk—have delivered...
Palo Alto Networks' (PANW) stock rose nearly 6% in the early premarket trading on Tuesday, after the cybersecurity firm reported better-than-expected...
Palo Alto Networks beat profit and sales estimates on increased demand for tougher tools to fight hackers. The cybersecurity firm also gave...
Here's my take on the calls for intensifying stagflation and why we won't see a 1970s repeat, my view of the Fed pick, and why I added to...
Wedbush Securities analyst Daniel Ives has placed his bets on cybersecurity as the “biggest subsector” in the technology sector in 2025.

Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.
The official website of Novo Nordisk is https://www.novonordisk.com.
According to Rankiteo, Novo Nordisk’s AI-generated cybersecurity score is 833, reflecting their Good security posture.
According to Rankiteo, Novo Nordisk currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.
According to Rankiteo, Novo Nordisk is not certified under SOC 2 Type 1.
According to Rankiteo, Novo Nordisk does not hold a SOC 2 Type 2 certification.
According to Rankiteo, Novo Nordisk is not listed as GDPR compliant.
According to Rankiteo, Novo Nordisk does not currently maintain PCI DSS compliance.
According to Rankiteo, Novo Nordisk is not compliant with HIPAA regulations.
According to Rankiteo,Novo Nordisk is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.
Novo Nordisk operates primarily in the Pharmaceutical Manufacturing industry.
Novo Nordisk employs approximately 64,615 people worldwide.
Novo Nordisk presently has no subsidiaries across any sectors.
Novo Nordisk’s official LinkedIn profile has approximately 2,243,164 followers.
Novo Nordisk is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.
Yes, Novo Nordisk has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/novonordisk.
Yes, Novo Nordisk maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novo-nordisk.
As of December 11, 2025, Rankiteo reports that Novo Nordisk has not experienced any cybersecurity incidents.
Novo Nordisk has an estimated 5,412 peer or competitor companies worldwide.
Total Incidents: According to Rankiteo, Novo Nordisk has faced 0 incidents in the past.
Incident Types: The types of cybersecurity incidents that have occurred include .
.png)
FreePBX Endpoint Manager is a module for managing telephony endpoints in FreePBX systems. Versions prior to 16.0.96 and 17.0.1 through 17.0.9 have a weak default password. By default, this is a 6 digit numeric value which can be brute forced. (This is the app_password parameter). Depending on local configuration, this password could be the extension, voicemail, user manager, DPMA or EPM phone admin password. This issue is fixed in versions 16.0.96 and 17.0.10.
Neuron is a PHP framework for creating and orchestrating AI Agents. In versions 2.8.11 and below, the MySQLWriteTool executes arbitrary SQL provided by the caller using PDO::prepare() + execute() without semantic restrictions. This is consistent with the name (“write tool”), but in an LLM/agent context it becomes a high-risk capability: prompt injection or indirect prompt manipulation can cause execution of destructive queries such as DROP TABLE, TRUNCATE, DELETE, ALTER, or privilege-related statements (subject to DB permissions). Deployments that expose an agent with MySQLWriteTool enabled to untrusted input and/or run the tool with a DB user that has broad privileges are impacted. This issue is fixed in version 2.8.12.
Neuron is a PHP framework for creating and orchestrating AI Agents. Versions 2.8.11 and below use MySQLSelectTool, which is vulnerable to Read-Only Bypass. MySQLSelectTool is intended to be a read-only SQL tool (e.g., for LLM agent querying, however, validation based on the first keyword (e.g., SELECT) and a forbidden-keyword list does not block file-writing constructs such as INTO OUTFILE / INTO DUMPFILE. As a result, an attacker who can influence the tool input (e.g., via prompt injection through a public agent endpoint) may write arbitrary files to the DB server if the MySQL/MariaDB account has the FILE privilege and server configuration permits writes to a useful location (e.g., a web-accessible directory). This issue is fixed in version 2.8.12.
Okta Java Management SDK facilitates interactions with the Okta management API. In versions 11.0.0 through 20.0.0, race conditions may arise from concurrent requests using the ApiClient class. This could cause a status code or response header from one request’s response to influence another request’s response. This issue is fixed in version 20.0.1.
The Auth0 Next.js SDK is a library for implementing user authentication in Next.js applications. When using versions 4.11.0 through 4.11.2 and 4.12.0, simultaneous requests on the same client may result in improper lookups in the TokenRequestCache for the request results. This issue is fixed in versions 4.11.2 and 4.12.1.

Get company history
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.
Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.
Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.
Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.
